Literature DB >> 22075600

Antifungal susceptibility and phylogeny of opportunistic members of the order mucorales.

Roxana G Vitale1, G Sybren de Hoog, Patrick Schwarz, Eric Dannaoui, Shuwen Deng, Marie Machouart, Kerstin Voigt, Wendy W J van de Sande, Somayeh Dolatabadi, Jacques F Meis, Grit Walther.   

Abstract

The in vitro susceptibilities of 66 molecularly identified strains of the Mucorales to eight antifungals (amphotericin B, terbinafine, itraconazole, posaconazole, voriconazole, caspofungin, micafungin, and 5-fluorocytosine) were tested. Molecular phylogeny was reconstructed based on the nuclear ribosomal large subunit to reveal taxon-specific susceptibility profiles. The impressive phylogenetic diversity of the Mucorales was reflected in susceptibilities differing at family, genus, and species levels. Amphotericin B was the most active drug, though somewhat less against Rhizopus and Cunninghamella species. Posaconazole was the second most effective antifungal agent but showed reduced activity in Mucor and Cunninghamella strains, while voriconazole lacked in vitro activity for most strains. Genera attributed to the Mucoraceae exhibited a wide range of MICs for posaconazole, itraconazole, and terbinafine and included resistant strains. Cunninghamella also comprised strains resistant to all azoles tested but was fully susceptible to terbinafine. In contrast, the Lichtheimiaceae completely lacked strains with reduced susceptibility for these antifungals. Syncephalastrum species exhibited susceptibility profiles similar to those of the Lichtheimiaceae. Mucor species were more resistant to azoles than Rhizopus species. Species-specific responses were obtained for terbinafine where only Rhizopus arrhizus and Mucor circinelloides were resistant. Complete or vast resistance was observed for 5-fluorocytosine, caspofungin, and micafungin. Intraspecific variability of in vitro susceptibility was found in all genera tested but was especially high in Mucor and Rhizopus for azoles and terbinafine. Accurate molecular identification of etiologic agents is compulsory to predict therapy outcome. For species of critical genera such as Mucor and Rhizopus, exhibiting high intraspecific variation, susceptibility testing before the onset of therapy is recommended.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22075600      PMCID: PMC3256695          DOI: 10.1128/JCM.06133-11

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  36 in total

1.  In vitro activities of amphotericin B, caspofungin, itraconazole, posaconazole, and voriconazole against 45 clinical isolates of zygomycetes: comparison of CLSI M38-A, Sensititre YeastOne, and the Etest.

Authors:  Marta Torres-Narbona; Jesús Guinea; José Martínez-Alarcón; Teresa Peláez; Emilio Bouza
Journal:  Antimicrob Agents Chemother       Date:  2006-12-28       Impact factor: 5.191

2.  Posaconazole as salvage therapy for zygomycosis.

Authors:  R N Greenberg; K Mullane; J-A H van Burik; I Raad; M J Abzug; G Anstead; R Herbrecht; A Langston; K A Marr; G Schiller; M Schuster; J R Wingard; C E Gonzalez; S G Revankar; G Corcoran; R J Kryscio; R Hare
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

3.  In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.

Authors:  F Sabatelli; R Patel; P A Mann; C A Mendrick; C C Norris; R Hare; D Loebenberg; T A Black; P M McNicholas
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

Review 4.  A higher-level phylogenetic classification of the Fungi.

Authors:  David S Hibbett; Manfred Binder; Joseph F Bischoff; Meredith Blackwell; Paul F Cannon; Ove E Eriksson; Sabine Huhndorf; Timothy James; Paul M Kirk; Robert Lücking; H Thorsten Lumbsch; François Lutzoni; P Brandon Matheny; David J McLaughlin; Martha J Powell; Scott Redhead; Conrad L Schoch; Joseph W Spatafora; Joost A Stalpers; Rytas Vilgalys; M Catherine Aime; André Aptroot; Robert Bauer; Dominik Begerow; Gerald L Benny; Lisa A Castlebury; Pedro W Crous; Yu-Cheng Dai; Walter Gams; David M Geiser; Gareth W Griffith; Cécile Gueidan; David L Hawksworth; Geir Hestmark; Kentaro Hosaka; Richard A Humber; Kevin D Hyde; Joseph E Ironside; Urmas Kõljalg; Cletus P Kurtzman; Karl-Henrik Larsson; Robert Lichtwardt; Joyce Longcore; Jolanta Miadlikowska; Andrew Miller; Jean-Marc Moncalvo; Sharon Mozley-Standridge; Franz Oberwinkler; Erast Parmasto; Valérie Reeb; Jack D Rogers; Claude Roux; Leif Ryvarden; José Paulo Sampaio; Arthur Schüssler; Junta Sugiyama; R Greg Thorn; Leif Tibell; Wendy A Untereiner; Christopher Walker; Zheng Wang; Alex Weir; Michael Weiss; Merlin M White; Katarina Winka; Yi-Jian Yao; Ning Zhang
Journal:  Mycol Res       Date:  2007-03-13

5.  In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents.

Authors:  Nikolaos G Almyroudis; Deanna A Sutton; Annette W Fothergill; Michael G Rinaldi; Shimon Kusne
Journal:  Antimicrob Agents Chemother       Date:  2007-04-23       Impact factor: 5.191

6.  Real-time PCR method for detection of zygomycetes.

Authors:  D Jane Hata; Seanne P Buckwalter; Bobbi S Pritt; Glenn D Roberts; Nancy L Wengenack
Journal:  J Clin Microbiol       Date:  2008-05-14       Impact factor: 5.948

7.  Molecular diagnostics of clinical strains of filamentous Basidiomycetes.

Authors:  G S de Hoog; A H Gerrits van den Ende
Journal:  Mycoses       Date:  1998 May-Jun       Impact factor: 4.377

Review 8.  Epidemiology and outcome of zygomycosis: a review of 929 reported cases.

Authors:  Maureen M Roden; Theoklis E Zaoutis; Wendy L Buchanan; Tena A Knudsen; Tatyana A Sarkisova; Robert L Schaufele; Michael Sein; Tin Sein; Christine C Chiou; Jaclyn H Chu; Dimitrios P Kontoyiannis; Thomas J Walsh
Journal:  Clin Infect Dis       Date:  2005-07-29       Impact factor: 9.079

9.  Molecular identification of zygomycetes from culture and experimentally infected tissues.

Authors:  Patrick Schwarz; Stéphane Bretagne; Jean-Charles Gantier; Dea Garcia-Hermoso; Olivier Lortholary; Françoise Dromer; Eric Dannaoui
Journal:  J Clin Microbiol       Date:  2006-02       Impact factor: 5.948

10.  In vitro susceptibility to 9 antifungal agents of 14 strains of Zygomycetes isolated from clinical specimens.

Authors:  M Otcenásek; V Buchta
Journal:  Mycopathologia       Date:  1994-12       Impact factor: 2.574

View more
  40 in total

1.  DNA barcoding in Mucorales: an inventory of biodiversity.

Authors:  G Walther; J Pawłowska; A Alastruey-Izquierdo; M Wrzosek; J L Rodriguez-Tudela; S Dolatabadi; A Chakrabarti; G S de Hoog
Journal:  Persoonia       Date:  2013-03-04       Impact factor: 11.051

2.  Etest cannot be recommended for in vitro susceptibility testing of mucorales.

Authors:  Rita Caramalho; Elisabeth Maurer; Ulrike Binder; Ricardo Araújo; Somayeh Dolatabadi; Cornelia Lass-Flörl; Michaela Lackner
Journal:  Antimicrob Agents Chemother       Date:  2015-04-06       Impact factor: 5.191

3.  Evaluation of the Gradient Concentration Strip Method for Antifungal Susceptibility Testing of Isavuconazole and Comparators for Mucorales Species.

Authors:  Pauline Vidal; Patrick Schwarz; Eric Dannaoui
Journal:  Antimicrob Agents Chemother       Date:  2019-09-23       Impact factor: 5.191

4.  Pulmonary mucormycosis due to Lichtheimia ramosa in a patient with HIV infection.

Authors:  Murat Kutlu; Cağrı Ergin; Ferda Bir; Süleyha Hilmioğlu-Polat; Ramazan Gümral; Ceyda Necan; Ali Koçyiğit; Selda Sayın-Kutlu
Journal:  Mycopathologia       Date:  2014-06-13       Impact factor: 2.574

5.  In Vitro Antifungal Activities against Moulds Isolated from Dermatological Specimens.

Authors:  Tzar Mohd Nizam; Rabiatul Adawiyah Ag Binting; Shafika Mohd Saari; Thivyananthini Vijaya Kumar; Marianayati Muhammad; Hartini Satim; Hamidah Yusoff; Jacinta Santhanam
Journal:  Malays J Med Sci       Date:  2016-05

6.  Multicenter evaluation of MIC distributions for epidemiologic cutoff value definition to detect amphotericin B, posaconazole, and itraconazole resistance among the most clinically relevant species of Mucorales.

Authors:  A Espinel-Ingroff; A Chakrabarti; A Chowdhary; S Cordoba; E Dannaoui; P Dufresne; A Fothergill; M Ghannoum; G M Gonzalez; J Guarro; S Kidd; C Lass-Flörl; J F Meis; T Pelaez; A M Tortorano; J Turnidge
Journal:  Antimicrob Agents Chemother       Date:  2015-01-12       Impact factor: 5.191

Review 7.  Therapeutic Challenges of Non-Aspergillus Invasive Mold Infections in Immunosuppressed Patients.

Authors:  Frederic Lamoth; Dimitrios P Kontoyiannis
Journal:  Antimicrob Agents Chemother       Date:  2019-10-22       Impact factor: 5.191

8.  A Revised Species Concept for Opportunistic Mucor Species Reveals Species-Specific Antifungal Susceptibility Profiles.

Authors:  Lysett Wagner; Sybren de Hoog; Ana Alastruey-Izquierdo; Kerstin Voigt; Oliver Kurzai; Grit Walther
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

9.  Comparison of the EUCAST and CLSI Broth Microdilution Methods for Testing Isavuconazole, Posaconazole, and Amphotericin B against Molecularly Identified Mucorales Species.

Authors:  Anuradha Chowdhary; Pradeep Kumar Singh; Shallu Kathuria; Ferry Hagen; Jacques F Meis
Journal:  Antimicrob Agents Chemother       Date:  2015-10-05       Impact factor: 5.191

Review 10.  [PCR-based diagnosis of mucormycosis in tissue samples].

Authors:  R Bialek; U E Zelck
Journal:  Pathologe       Date:  2013-11       Impact factor: 1.011

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.